Neumora Therapeutics Inc (NMRA) Stock Price, Quote & News

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associ...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 760 0900

Website: www.neumoratx.com

Address:

260 Arsenal Place, Suite 1, Watertown, United States

SizeableVirus Aug. 7 at 11:31 PM

$NMRA The whole market is in the green and this shit is in the red, as usual, haha.

0 · Reply

colmmcnabola Aug. 3 at 10:09 AM

$NMRA Earnings call this week, positive or negative?

0 · Reply

Buying_Low_Selling_High Jul. 31 at 1:50 PM

$NMRA So basically even the positive news is not enough to move this higher. A bit more active communication from management team would be helpful.

2 · Reply

Keystone1 Jul. 27 at 6:20 PM

$NMRA love to see a 2$ close!!!

0 · Reply

MrStockFlop Jul. 27 at 5:54 PM

$NMRA very nice price action! Hope this will double after next week earnings 🤞🏻

0 · Reply

Buying_Low_Selling_High Jul. 27 at 3:57 PM

$NMRA This should be 20-30% up on this news. Mega news on largest market opportunity. Huge upside Loading .....

0 · Reply

InvestorCG Jul. 27 at 2:36 PM

$NMRA Under 100k shares traded on this news. Kinda crazy. Now that they have the weight loss drug back on track, I think this one has hope again.

2 · Reply

InvestorCG Jul. 27 at 1:49 PM

$NMRA https://finance.yahoo.com/healthcare/articles/neumora-therapeutics-reports-favorable-nmra-110000834.html

0 · Reply

SizeableVirus Jul. 24 at 3:13 PM

$NMRA fucking TRASH!

1 · Reply

Kaltycoon Jul. 23 at 6:49 PM

$NMRA any news about obesity drug?

1 · Reply

Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study

Jul 27, 2026, 7:00 AM EDT - 14 days ago

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

2026-07-13T13:25:49.000Z - 4 weeks ago

Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital

Jul 1, 2026, 8:00 AM EDT - 5 weeks ago

Neumora Therapeutics Slides: Corporate presentation

2026-06-18T12:11:53.000Z - 7 weeks ago

Neumora Therapeutics price target lowered to $4 from $6 at Mizuho

Jun 17, 2026, 7:00 AM EDT - 7 weeks ago

Neumora Therapeutics Slides: Investor presentation

2026-06-16T11:23:08.000Z - 7 weeks ago

Neumora Therapeutics price target lowered to $5 from $8 at Needham

2026-06-16T10:11:19.000Z - 7 weeks ago

Neumora Therapeutics price target lowered to $7 from $18 at H.C. Wainwright

2026-06-15T22:35:06.000Z - 2 months ago

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102

LBRX

2026-06-15T12:55:07.000Z - 2 months ago

Neumora Therapeutics announces KOASTAL studies miss primary endpoint

Jun 15, 2026, 8:13 AM EDT - 2 months ago

Neumora Therapeutics scraps depression drug after two late-stage trial failures

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

May 27, 2026, 4:00 PM EDT - 2 months ago

Neumora Therapeutics Transcript: AGM 2026

May 19, 2026, 1:35 PM EDT - 2 months ago

Neumora Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 4:05 PM EDT - 3 months ago

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

2026-05-07T15:39:57.000Z - 3 months ago

Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)

May 7, 2026, 7:00 AM EDT - 3 months ago

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 7:00 AM EDT - 3 months ago

Neumora Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Neumora Therapeutics Slides: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Neumora Therapeutics Quarterly report: Q1 2026

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Neumora Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Neumora Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 10:15 AM EDT - 4 months ago

Neumora Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

2026-04-02T14:37:16.000Z - 4 months ago

Neumora Therapeutics management to meet with Piper Sandler

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Neumora Therapeutics Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Neumora Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Neumora Therapeutics Earnings release: Q4 2025

2026-03-30T11:00:07.000Z - 4 months ago

Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)

Mar 30, 2026, 6:53 AM EDT - 4 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 6:30 AM EDT - 4 months ago

Neumora Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

2026-03-02T18:05:39.000Z - 5 months ago

Neumora Therapeutics management to meet virtually with Needham

2026-02-17T11:06:03.000Z - 6 months ago

Neumora upgraded to Outperform from Market Perform at William Blair

Feb 11, 2026, 4:00 PM EST - 6 months ago

Neumora Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 10, 2026, 7:00 AM EST - 6 months ago

Neumora Therapeutics Slides: Corporate presentation

Feb 4, 2026, 7:00 AM EST - 6 months ago

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12T10:25:32.000Z - 7 months ago

Neumora Therapeutics initiated with an Outperform at Leerink

2026-01-06T13:05:25.000Z - 7 months ago

Neumora Therapeutics price target raised to $6 from $5 at Mizuho

Jan 5, 2026, 8:00 AM EST - 7 months ago

Neumora Therapeutics Transcript: Study Result

Jan 5, 2026, 8:00 AM EST - 7 months ago

Neumora Therapeutics Press release: Study Result

Jan 5, 2026, 8:00 AM EST - 7 months ago

Neumora Therapeutics Slides: Study Result

2026-01-05T11:42:16.000Z - 7 months ago

Neumora Therapeutics announces results from NMRA-511 Phase 1b study

2026-01-05T11:41:35.000Z - 7 months ago

Neumora Therapeutics highlights 2026 pipeline strategy

Jan 5, 2026, 6:35 AM EST - 7 months ago

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Jan 5, 2026, 6:30 AM EST - 7 months ago

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

2025-12-01T10:40:34.000Z - 9 months ago

Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital

Nov 12, 2025, 2:00 PM EST - 9 months ago

Neumora Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 2:30 PM EST - 9 months ago

Neumora Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 9 months ago

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 7:00 AM EST - 9 months ago

Neumora Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Neumora Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 7:00 AM EST - 10 months ago

Neumora Therapeutics to Participate in Upcoming Conferences in November

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Neumora Therapeutics Transcript: R&D Day 2025

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Neumora Therapeutics Press release: FY 2025

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Neumora Therapeutics Slides: FY 2025

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Oct 27, 2025, 6:30 AM EDT - 10 months ago

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Oct 1, 2025, 7:00 AM EDT - 11 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27

Sep 9, 2025, 1:00 PM EDT - 11 months ago

Neumora Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics to Participate in Upcoming Conferences in September

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation

Jul 23, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 9, 2025, 4:00 PM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

May 16, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

Apr 4, 2025, 4:05 PM EDT - 1 year ago

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 30, 2025, 4:00 PM EDT - 1 year ago

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 26, 2025, 2:19 AM EDT - 1 year ago

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

SizeableVirus Aug. 7 at 11:31 PM

$NMRA The whole market is in the green and this shit is in the red, as usual, haha.

0 · Reply

colmmcnabola Aug. 3 at 10:09 AM

$NMRA Earnings call this week, positive or negative?

0 · Reply

Buying_Low_Selling_High Jul. 31 at 1:50 PM

$NMRA So basically even the positive news is not enough to move this higher. A bit more active communication from management team would be helpful.

2 · Reply

Keystone1 Jul. 27 at 6:20 PM

$NMRA love to see a 2$ close!!!

0 · Reply

MrStockFlop Jul. 27 at 5:54 PM

$NMRA very nice price action! Hope this will double after next week earnings 🤞🏻

0 · Reply

Buying_Low_Selling_High Jul. 27 at 3:57 PM

$NMRA This should be 20-30% up on this news. Mega news on largest market opportunity. Huge upside Loading .....

0 · Reply

InvestorCG Jul. 27 at 2:36 PM

$NMRA Under 100k shares traded on this news. Kinda crazy. Now that they have the weight loss drug back on track, I think this one has hope again.

2 · Reply

InvestorCG Jul. 27 at 1:49 PM

$NMRA https://finance.yahoo.com/healthcare/articles/neumora-therapeutics-reports-favorable-nmra-110000834.html

0 · Reply

SizeableVirus Jul. 24 at 3:13 PM

$NMRA fucking TRASH!

1 · Reply

Kaltycoon Jul. 23 at 6:49 PM

$NMRA any news about obesity drug?

1 · Reply

Keystone1 Jul. 17 at 2:29 PM

$NMRA Up 7.5%, let’s go!

0 · Reply

Keystone1 Jul. 17 at 1:46 PM

$NMRA Wow, it’s green in a sea of red! Not bad!

0 · Reply

anachartanalyst Jul. 13 at 3:02 PM

$NMRA https://anachart.com/wp-content/uploads/2026/07/1783954911_soc-img.jpg

1 · Reply

MrStockFlop Jul. 10 at 9:25 AM

$NMRA For your confirmation bias. Have a good weekend boys! https://finance.yahoo.com/healthcare/articles/why-neumora-therapeutics-inc-nmra-055351885.html

2 · Reply

Keystone1 Jul. 9 at 8:43 PM

$NMRA Big jump after hours! Any news?

0 · Reply

MrStockFlop Jul. 9 at 8:36 PM

$NMRA What just happened? 8,5% jump in after hours. Any news?

0 · Reply

Keystone1 Jul. 7 at 5:09 PM

$NMRA Nice 7% move! Anything driving the stock?

0 · Reply

AshleySchaeffer_BMW Jul. 7 at 5:08 PM

$NMRA watch us get acquired in the coming weeks, will lol at shorts then....

2 · Reply

MrStockFlop Jul. 7 at 10:52 AM

$NMRA Can we break 1.80 today?

1 · Reply

SizeableVirus Jul. 1 at 8:42 PM

$NMRA Get ready, because tomorrow it’s dropping more than 10%...

3 · Reply

Kaltycoon Jun. 30 at 2:11 PM

$NMRA what do we think about lawsuits here? I see all over the place. Recovery was nice after failure.

2 · Reply

Keystone1 Jun. 30 at 1:34 PM

$NMRA 1.81 and climbing! Let’s go.

0 · Reply

Market Cap	302.01M
Revenue (ttm)	0.00
Net Income (ttm)	-236.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.75

Volume	580,700
Avg Vol	2,189,812
Day's Range	N/A - N/A
Shares Out	185.28M
Stochastic %K	64%
Beta	2.75
Analysts	Sell
Price Target	$6.14